J&J boasts improved cardio safety with SGLT2 franchise drug Invokana - Endpoints News

Endpoints News

J&J boasts improved cardio safety with SGLT2 franchise drug Invokana Endpoints News J&J scored vitally important cardio safety data for its SGLT2 diabetes drug Invokana in a large Phase III outcomes study, which it happily shared with researchers at the annual American Diabetes Association conference in San Diego on Monday afternoon. and more »

from Health - Google News http://ift.tt/2shcYiG